Thousands of previously unknown proteins discovered
On May 6, 2026, a group of international researchers announced they had discovered 1,700 new proteins. The research…
-
-
UVA Study Reveals How New Weight-Loss Drugs Reshape the Brain
On May 6, 2026, In a study published in Nature, a team led by University of Virginia (UVA)…
-
USC launches transformational AI initiative with $200 million gift
On May 5, 2026, the University of Southern California (USC) announced a transformational initiative that will leverage AI…
-
Canada approves second generic semaglutide, the first G7 country to do so
On May 1, 2026, Health Canada authorized a second generic semaglutide injection. Health Canada is currently reviewing seven other…
-
Researchers create groundbreaking first-draft map of genetic interactions within human cells
On Apr. 30, 2026, researchers at the University of Bonn and University Hospital Bonn have created a groundbreaking…
-
Artificial Intelligence | Biotechnology | Diagnostics | Disease | Genomics | Neurology | Non-Profit Research | Oncology | Therapeutics
Biohub Launches the Virtual Biology Initiative to Galvanize a Global Effort to Create the Open Data Foundation for AI-Accelerated Biolog
On Apr. 29, 2026, Biohub announced the Virtual Biology Initiative, a landmark five-year initiative to galvanize a global…
-
Scientists Create First-Ever ‘Smell Map’
On Apr. 28, 2026, scientists Sandeep (Robert) Datta, professor of neurobiology in the Blavatnik Institute at Harvard Medical…
-
Girl’s sight restored after ‘life-changing’ gene therapy
On Apr. 23, 2026, a research team at the University College London (UCL) and Great Ormond Street Hospital…
-
Biotechnology | Disease | FDA | Therapeutics
FDA Approves First-Ever Gene Therapy for Treatment of Genetic Hearing Loss
On Apr. 23, 2026, the U.S. Food and Drug Administration (FDA) approved Otarmeni (lunsotogene parvec-cwha), the first-ever dual…
-
Kailera nets $625M, biotech’s biggest-ever IPO
On Apr. 17, 2026, Kailera Therapeutics, a high-profile drug startup aiming to compete with Novo Nordisk and Eli…
-
Biotechnology | Diagnostics | Disease | Genomics | Oncology | Therapeutics
Roche Expands Foundation Medicine With Acquisition of SAGA Diagnostics’ Tumor-Informed Molecular Residual Disease Platform for $595 million
On Apr. 15, 2026, Foundation Medicine, an independent affiliate of the Roche group, announced it is set to…
-
Scientists reverse brain aging, with a nasal spray
On Apr. 14, 2026, a landmark study from researchers at the Texas A&M University Naresh K. Vashisht College…
-
Novo Nordisk partners with OpenAI in weight loss drug race
On Apr. 14, 2026, Novo Nordisk, the maker of popular weight-loss drugs Ozempic and Wegovy, is partnering with OpenAI…
-
Biotechnology | Disease | FDA | Therapeutics
FDA Approves New High Dose Regimen of SPINRAZA® (nusinersen) for Spinal Muscular Atrophy
On Mar. 30, 2026, Biogen announced that the High Dose Regimen of SPINRAZA® (nusinersen), which is comprised of…
-
Implantable ‘Living Pharmacy’ Produces Multiple Drugs Inside the Body
On Mar. 27, 2026, A multi-institutional team of scientists, co-led by Northwestern University, has taken a crucial step…
-
Biotechnology | Disease | FDA | Pharmaceutical | Rare Disease | Stem Cell
Rocket Pharmaceuticals Announces FDA Approval of KRESLADI™ for Pediatric Patients with Severe Leukocyte Adhesion Deficiency-I (LAD-I)
On Mar. 27, 2026, Rocket Pharmaceuticals announced that the U.S. Food and Drug Administration(FDA) has granted accelerated approval…
-
Biotechnology | Disease | Neurology | Oncology | Pharmaceutical | Quantum
Merck to Acquire Terns Pharmaceuticals for $5.7 Billion, Expanding Its Hematology Pipeline With TERN-701, a Novel Candidate for Chronic Myeloid Leukemia
On Mar. 25, 2026, Merck, and Terns Pharmaceuticals, a clinical-stage oncology company, announced that the companies have entered…
-
New enzyme atlas rewrites decades of biology research
On Mar. 23, 2026, The Walter and Eliza Hall Institute of Medical Research (WEHI) researchers have led a…
-
An analysis of 2.2 million people reveals shared and substance-specific genetic pathways for addiction risk
On Mar. 20, 2026, researchers of a Rutgers Health–led study led by Holly Poore, a faculty instructor of psychiatry…
-
Biotechnology | Disease | FDA | Therapeutics
FDA approves new higher-dose version of Wegovy shots
On Mar. 19, 2026, The U.S. Food and Drug Administration approved a 7.2-milligram dose of Danish drugmaker Novo…
-
New Genetic Risk Score Better Predicts Diabetes, Obesity and Downstream Complications
On Mar. 16, 2026, investigators from Mass General Brigham announce they have built metabolic polygenic risk scores (PRS) for predicting…
-
Biotechnology | Disease | Imaging | Neurology | Therapeutics
RNA barcodes enable high-speed mapping of connections in the brain
On Mar. 13, 2026, a research team lead by Boxuan Zhao, a professor of cell and developmental biology…
-
Biotechnology | Disease | FDA
FDA approves Novo Nordisk’s Sogroya® as first and only once-weekly, long-acting growth hormone for three additional pediatric indications
On Feb. 27, 2026, Novo Nordisk announced that the US Food and Drug Administration (FDA) has approved three…
-
Study finds First-ever in-utero stem cell therapy for fetal spina bifida repair is safe
On Feb. 26, 2026, A University of California Davis Health research team has safely performed the world’s first spina…
-
MAP-Xing malaria protein complexes
On Dec. 12, 2025, an international research team headed by scientists from Nanyang Technological University, Singapore and the…
-
Cardiology | Diagnostics | Disease | Energy | Environmental | EPA | Genomics | Neurology | Oncology | U.S. Congress | Women's Health
EPA revokes scientific finding that underpinned US fight against climate change
On Feb. 12 2026, the Trump administration revoked a scientific finding that long has been the central basis…
-
Genentech’s Fenebrutinib First Investigational Medicine in Over a Decade That Reduces Disability Progression in Multiple Sclerosis
On Feb. 7, 2026, Genentech, a member of the Roche Group, announced late-breaking data from the Phase III…
-
Statins do not cause the majority of side effects listed in package leaflets
On Feb. 6, 2026, a study led by researchers at Oxford Population Health reported that statins do not…
-
UND leads $20 million federal initiative to transform diabetes care for seniors
On Feb. 5, 2026, the University of North Dakota (UND) announced it is leading a major national effort…
-
Experimental pill dramatically reduces ‘bad’ cholesterol
On Feb. 4, 2026, researchers from UT Southwestern Medical Center report that an experimental pill called enlicitide slashed…
